What Do Negative vs. Positive ANCA Results Mean in EGPA?
At a Glance
A negative ANCA test is common in EGPA and does not mean the disease is mild or rule out vasculitis. ANCA-negative disease more often involves the heart, lungs, and digestive tract, while ANCA-positive disease more often affects the kidneys, nerves, and skin; either pattern can occur in any patient.
In this answer
3 sections
Being ANCA-negative does not mean your Eosinophilic granulomatosis with polyangiitis (EGPA) is less severe. Instead, your ANCA status helps your doctors understand what type of symptoms and organ risks you are more likely to experience. EGPA generally presents with overlapping clinical patterns: one driven more by a buildup of eosinophils in tissues (usually ANCA-negative), and one driven more by small blood vessel inflammation (usually ANCA-positive) [1][2]. However, these are tendencies, not absolute rules—any patient can develop any symptom.
What is ANCA?
ANCA stands for antineutrophil cytoplasmic antibodies. These are immune proteins associated with abnormal inflammation and blood-vessel injury [1]. In EGPA, doctors look specifically for an ANCA type called MPO-ANCA [1].
It is very common to be ANCA-negative. In fact, roughly 60% of people with EGPA do not have these specific antibodies in their blood [1]. A negative ANCA test does not mean you do not have EGPA or vasculitis, and a positive test does not prove the diagnosis on its own—diagnosis depends on your entire clinical picture [3][4].
Different Patterns, Not Different Diseases
It is crucial to understand that your ANCA status does not lock you into a specific set of symptoms. An ANCA-negative patient can still experience kidney or nerve issues, and an ANCA-positive patient can still have heart or lung problems. Your care team will comprehensively monitor all your organs regardless of your test results [5][6].
However, studies show the two groups do have different average tendencies:
The ANCA-Negative Tendencies (Heart and Lungs)
When you are ANCA-negative, your EGPA tends to be driven by a buildup of eosinophils (a specialized type of white blood cell) infiltrating your tissues [1].
If you are ANCA-negative, studies show a higher average risk of:
- Heart involvement: ANCA-negative patients are more likely to experience cardiac issues, such as inflammation of the heart muscle (myocarditis) or heart failure [7][5]. Because heart involvement can sometimes be silent but is a major factor in long-term health, a baseline assessment (usually including a clinical history, ECG, and echocardiogram) is highly recommended [8][6]. A cardiac MRI may be ordered if these initial tests or your symptoms raise clinical suspicion [8].
- Lung and airway symptoms: While asthma and sinus issues are highly common across all EGPA patients, ANCA-negative patients often have more pulmonary infiltrates (clusters of inflammation in the lungs) and nasal polyps (noncancerous growths in the nasal passages) [9][3].
- Gastrointestinal issues: Eosinophils can accumulate in the digestive tract, leading to stomach pain, diarrhea, or other GI symptoms [3].
The ANCA-Positive Tendencies (Kidneys and Nerves)
If you are ANCA-positive, your disease tends to behave more like a classic vasculitis—inflammation of the small blood vessels [1][2].
ANCA-positive patients generally have a higher average risk of:
- Kidney involvement: The tiny blood vessels in the kidneys can become inflamed (glomerulonephritis), which can lead to chronic kidney disease if not treated promptly [10][11].
- Nerve damage: Peripheral neuropathy, which causes numbness, tingling, pain, or weakness in the hands and feet, is significantly more common in ANCA-positive patients [10][12].
- Skin rashes: Small vessel inflammation can cause purpura, which presents as small purple or red spots on the skin [10][6].
When to Seek Immediate Medical Care
Because EGPA can affect vital organs in both ANCA-negative and ANCA-positive patients, do not wait for your next routine appointment if you experience serious symptoms. Seek urgent or emergency care if you develop:
- New severe chest pain or a racing, irregular heartbeat
- Severe shortness of breath, especially at rest
- Coughing up blood
- Fainting or sudden dizziness
- Sudden new weakness, such as an inability to lift your foot (foot drop)
- Severe abdominal pain or signs of gastrointestinal bleeding
- A sudden, drastic drop in how much you urinate
Does ANCA Status Determine Prognosis or Treatment?
Many patients assume that being ANCA-negative means a lower chance of relapse or a better overall prognosis, but survival and relapse rates depend heavily on which organs are involved and the extent of the damage, rather than your ANCA status alone [5][11][13]. While ANCA-positive patients may face long-term risks from kidney or nerve issues [11], ANCA-negative patients face substantial risks from potential heart and lung involvement [7][5].
Furthermore, your ANCA status alone does not determine which immunosuppressive or biologic drugs you will receive [1]. Treatment decisions are primarily driven by which organs are affected, the severity of the inflammation, and your overall health [14]. Your medical team uses your ANCA status as one piece of a larger puzzle to tailor your monitoring and care plan [6].
Common questions in this guide
Can I have EGPA if my ANCA test is negative?
Is ANCA-negative EGPA less severe than ANCA-positive EGPA?
What health checks are important after an ANCA-negative EGPA result?
What does an MPO-ANCA-positive result suggest in EGPA?
Does my ANCA result decide my EGPA treatment and outlook?
Which EGPA symptoms require urgent medical care?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Was MPO-ANCA specifically tested on my labs, and what were the exact date and results?
- 2.Given my overall clinical picture, what baseline organ screenings—such as an ECG and echocardiogram for my heart, or urine tests and blood pressure checks for my kidneys—do I need?
- 3.How frequently will we monitor my heart and lungs versus my kidneys and nerves?
- 4.How does my specific organ involvement (rather than just my ANCA status) influence which immunosuppressive or biologic therapies you recommend?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis.
Moiseev S, Bossuyt X, Arimura Y, et al.
American journal of respiratory and critical care medicine 2020; (202(10)):1360-1372 doi:10.1164/rccm.202005-1628SO.
PMID: 32584187 - 2
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status.
Lyons PA, Peters JE, Alberici F, et al.
Nature communications 2019; (10(1)):5120 doi:10.1038/s41467-019-12515-9.
PMID: 31719529 - 3
A Case of Antineutrophil Cytoplasmic Antibody (ANCA) - Negative Eosinophilic Granulomatosis with Polyangiitis (EGPA) with Nasal Polyps and Peripheral Neuropathy.
Perić A, Labus M, Vukomanović Đurđević B
Sage open pathology 2026; (19()):30502098261451762 doi:10.1177/30502098261451762.
PMID: 42152982 - 4
How to improve the histopathological diagnosis of systemic vasculitides in daily practice?
Honsová E
Ceskoslovenska patologie 2020; (56(2)):68-73.
PMID: 32493022 - 5
Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America.
Doubelt I, Cuthbertson D, Carette S, et al.
ACR open rheumatology 2021; (3(6)):404-412 doi:10.1002/acr2.11263.
PMID: 34032390 - 6
Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss).
Nguyen Y, Guillevin L
Seminars in respiratory and critical care medicine 2018; (39(4)):471-481 doi:10.1055/s-0038-1669454.
PMID: 30404114 - 7
[Cardiac involvement in Churg-Strauss syndrome].
Brucato A, Maestroni S, Masciocco G, et al.
Giornale italiano di cardiologia (2006) 2015; (16(9)):493-500 doi:10.1714/1988.21524.
PMID: 26418389 - 8
Severe biventricular thrombosis in eosinophilic granulomatosis with polyangiitis: a case report.
Hamudi J, Karkabi B, Zisman D, Shiran A
European heart journal. Case reports 2020; (4(6)):1-5 doi:10.1093/ehjcr/ytaa417.
PMID: 33442628 - 9
ANCA negative eosinophilic granulomatosis with polyangiitis (EGPA) presenting with left ventricular thrombus: An appreciation of distinct phenotypes and eosinophilic driven pathogenesis.
Chaivannacoopt K, Flanagan E
Respirology case reports 2022; (10(10)):e01033 doi:10.1002/rcr2.1033.
PMID: 36090017 - 10
Antineutrophil Cytoplasmic Antibodies and Organ-Specific Manifestations in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis.
Chang HC, Chou PC, Lai CY, Tsai HH
The journal of allergy and clinical immunology. In practice 2021; (9(1)):445-452.e6 doi:10.1016/j.jaip.2020.07.038.
PMID: 32771687 - 11
Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).
Durel CA, Berthiller J, Caboni S, et al.
Arthritis care & research 2016; (68(3)):374-87 doi:10.1002/acr.22686.
PMID: 26315340 - 12
Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis.
Rubenstein E, Maldini C, Vaglio A, et al.
The Journal of rheumatology 2023; (50(11)):1446-1453 doi:10.3899/jrheum.2023-0325.
PMID: 37739478 - 13
The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?
Duran E, Bostan OC, Bilgin E, et al.
Internal and emergency medicine 2022; (17(3)):743-751 doi:10.1007/s11739-021-02863-0.
PMID: 34628561 - 14
Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis.
Kolios AGA, Lutterotti A, Kulcsar Z, et al.
Clinical immunology (Orlando, Fla.) 2021; (222()):108574 doi:10.1016/j.clim.2020.108574.
PMID: 32805452
This page explains how ANCA status may relate to EGPA organ involvement for informational purposes only and does not constitute medical advice. Ask your care team to interpret your results and recommend appropriate monitoring or treatment.
Get notified when new evidence is published on Eosinophilic granulomatosis with polyangiitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.